Physician profile
Stephen E Mikos
NPI 1770566523
$1,991.82
in general payments reported to CMS, 2019-2025
20 companies · $29.09 in 2025
The $29.09 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $438 · 2021: $407 · 2022: $250 · 2023: $164 · 2024: $286 · 2025: $29.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.29 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.41 | 2021-2025 | |
| Allergan, INC. | $321.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.17 | 2019-2022 | |
| Amgen INC. | $121.64 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $116.47 | 2019-2021 | |
| Pfizer INC. | $99.17 | 2020-2022 | |
| Amarin Pharma, INC. | $86.20 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $79.79 | 2019-2024 | Livalo |
| Astellas Pharma US INC | $76.76 | 2019-2023 | |
| Novo Nordisk INC | $75.23 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $55.41 | 2020-2021 | |
| Eisai INC. | $38.58 | 2021-2024 | |
| Esperion Therapeutics, INC. | $36.94 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $28.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.89 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $22.06 | 2023 | Biotronik |
| Lilly USA, LLC | $18.17 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.27 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.15 | 2022 | |
| Linus Health, INC. | $14.83 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mikos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.